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ent cost-containment policies, i.e. restriction for use of DES,
along with the uncertainty surrounding the estimate.
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OBJECTIVES: Lipodystrophy may greatly impairs quality of life
(QoL). Nevertheless, the recognition of the scientiﬁc value of
QoL and more broadly the patient’s perspective in evaluating
therapies is questioned. It may be useful to quantify the added
value of the patient’s perspective, using correlations between
patient-reported outcomes (PRO’s) and clinician-reported and
biological outcomes. METHODS: We performed a cross-
sectional survey in 143 HIV French outpatients with lipodystro-
phy. Clinical and demographic data were collected. Patients 
completed a new speciﬁc lipodystrophy questionnaire “Assess-
ment of Body Change and Distress” (ABCD), consisting of three
parts: signs of lipodystrophy (six items), global satisfaction (n =
1) and 20 items evaluating QoL. An HIV speciﬁc (MOS-HIV) 
and generic (SF-12) QoL questionnaires were also ﬁlled-in.
RESULTS: Mean age was 43 ± 10yrs (71% of men), and mean
duration of HAART was 4.5 ± 1.7yrs. ABCD QoL score is
weakly or no associated with viral load (r = 0.03), CD4 count
(r = 0.13) and CDC classiﬁcation (p = NS). Its correlation with
the clinician’s report of number of sites of lipodystrophy is weak
(r = 0.17). Correlations between different PRO’s are logically
higher. ABCD QoL score is more correlated with the patient’s
report of number of sites of lipodystrophy (r = 0.39) and with
satisfaction (r = 0.58). ABCD QoL score is correlated with health
distress and social dimensions of the MOS-HIV (r > 0.6) and
with mental component of the SF-12 (r = 0.65), but not with
physical dimensions of these questionnaires (r < 0.2). CON-
CLUSIONS: PRO’s are weakly correlated with biological
markers, and although overlapping, each one of PRO’s measures
a distinct concept. Clinicians cannot infer the QoL of their
patients neither from a viral load nor from a clinical exam. The
patient’s perspective is essential in medical decision making and
so it is with lipodystrophy.
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OBJECTIVES: To prospectively evaluate the health-related
quality of life of patients with Parkinson’s disease (PD) in
Germany over a 12 months observation period. METHODS:
The study included 145 patients with PD (mean age: 67.3 ± 9.6
years) in Germany. Patients were asked to complete the EQ-5D,
Par-kinson’s Disease Quality of life questionnaire (PDQL). 
and the Par-kinson’s Disease questionnaire-39 (PDQ-39). In
addition, the occurrence of depression and dementia were inves-
tigated using the Beck’s Depression Inventory (BDI) and the
Mini-Mental-State-Examination (MMSE). Evaluations were per-
formed at baseline, three, six and 12 months. Disease severity
was documented by the Uniﬁed Parkinson’s Disease Rating Scale
(UPDRS) and the Hoehn & Yahr (HY) scale. RESULTS: At base-
line mean VAS-value was 59.9 ± 18.0 and mean EQ-5D index
was 0.74 ± 0.25. HRQoL of patients suffering from dyskinesias
(47.5) were lower than in patients without dyskinesias (61.7). In
HY-stage I mean VAS was 72.8 ± 16.9 vs. HY V 45.7 ± 10.6. At
12 months the overall PDQ-39 score declined slightly from base-
line 29.4 ± 17.4 (n = 137) to 25.6 ± 16.2 (n = 128). Similar results
were found for the PDQL overall score (118.6 ± 27.5 (n = 87)
compared to 122.8 ± 26.1 (n = 72)) and the EQ-5D index (0.74
± 0.25 (n = 115) compared to 0.74 ± 0.25 (n = 115). No signif-
icant changes were found for the clinical scores (UPDRS and
Hoehn & Yahr scale) and the psychometric questionnaires
(MMSE and BDI). CONCLUSIONS: The PDQ-39, PDQL and
the EQ-5D are instruments delivering stable test results for PD
patients. There is no signiﬁcant change during the 12-months
abservation period in all used instruments. As this study will
have a follow-up up to three years a more detailed analysis of
time-dependent changes of HRQoL will be possible. Depression
and motor complications are the factors with the highest impact
on health-related quality of life in PD patients.
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OBJECTIVES: Gastroesophageal Reﬂux Disease is a chronic
condition whose symptoms cause great impairment on a patient’s
quality of life. Our aim was to evaluate GERD patients Health
Related Quality of Life (HRQoL) and its association to clinical
status. METHODS: A cross-sectional observational multicentre
cost of illness study was conducted in the urban area of Milan.
The study involved 317 patients (mean age 59 years, 58%
female) sequentially enrolled by 47 General Practitioners. Infor-
mation was collected investigating demographic, clinical, eco-
nomic and quality of life variables. To assess QoL in GERD
patients we used a generic (EuroQol) and a speciﬁc (Quality of
Life in Reﬂux and Dyspepsia, QOLRAD heartburn version)
questionnaire. We report on QoL data. RESULTS: A strong
impairment in the HRQoL was documented both with EQ-5D
and QOLRAD instruments. Patients reported an average value
of 64.4 in the EQ-VAS, signiﬁcantly lower compared to general
population. The EQ-proﬁle indicated that “pain/discomfort”
and “anxiety/depression” were the most impaired domains. We
converted the EQ-proﬁle in economic utility score by means of
values from UK and Catalonia. Using the UK conversion values
we had a utility mean score of 0.70 (±0.23), using the Catalonia
conversion values the mean score was 0.79 (±0.21). The EQ-VAS
value signiﬁcantly decreased with age, heartburn, epigastric pain,
odynophagia, globus sensation, relapse of symptoms and with
all the QOLRAD domains. The most impaired QOLRAD
domain was “food/drink problems”, the less one was “physi-
cal/social functioning” with a mean value of 4.95 and 5.74
respectively (one worst, seven best imaginable health state). The
internal consistency tested with Cronbach’s alpha was >0.8 for
all domains. Results with QOLRAD were conﬁrmed by those
with EQ-5D. CONCLUSIONS: This is the ﬁrst Italian study on
quality of life of GERD patients visited by GP’s, highlighting that
this disease signiﬁcantly impairs global patients’ HRQoL.
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